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doi:10.1Despite surgical resection, patientswith early-stage (I to IIIA)non–small cell lung cancer (NSCLC) are at consider-
able risk of recurrence anddeath from their lung cancer. In recent years,multiple, large, randomized trials assessing
the efficacy of adjuvant chemotherapy for resected NSCLC have been reported. Three of 6 trials with 300 or more
patients with early-stage NSCLC have demonstrated that adjuvant cisplatin-based chemotherapy can significantly
improve 5-year survival in carefully selected patientswith resectedNSCLC. These benefits have been confirmed in
ameta-analysis ofmodern cisplatin-based adjuvant trials. Themost consistent benefit has been reported in patients
with resected stage II and IIIA NSCLC. The benefit of adjuvant chemotherapy in patients with resected stage IB
NSCLC is less concrete. Herein, we review the results of the major adjuvant chemotherapy trials and their impli-
cations for the treatment of patients with completely resected NSCLC. A future challenge will be to identify the
subsets of patients whowill derive the greatest benefit from adjuvant chemotherapy. Current trials are also under-
way to define the role of novel targeted therapies, such as inhibitors of the epidermal growth factor receptor and
monoclonal antibodies, in adjuvant treatment strategies. (J Thorac Cardiovasc Surg 2012;144:S39-42)The most effective treatment of early-stage (I to IIIA) non–
small cell lung cancer (NSCLC) is surgical resection. De-
spite optimal surgery, a substantial percentage of patients
with stage I to IIIA NSCLC subsequently relapse and die
of their lung cancer.1 Studies that suggested adjuvant che-
motherapy could prolong survival for some patients with
early-stage lung cancer began to emerge. A number of trials
have since documented that the use of chemotherapy in the
postoperative setting can prolong survival. The present re-
view summarizes the evidence showing the benefit from ad-
juvant chemotherapy for specific subgroups of patients with
early-stage NSCLC.EVIDENCE FOR ADJUVANT CHEMOTHERAPY
Small randomized trials of patients with early-stage
NSCLC performed during the past 30 years were jointly an-
alyzed in an individual patient data meta-analysis published
in 1995.2 That analysis, involving more than 4300 patients,
showed a strong trend toward improved survival of approx-
imately 5% at 5 years for patients with resected early-stage
NSCLC treated with adjuvant cisplatin-based chemother-
apy compared with those on observation alone (hazard ratio
[HR], 0.87; 95% confidence interval [CI], 0.74 to 1.02; P¼e Lowe Center for Thoracic Oncology, Department of Medical Oncology,
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The Journal of Thoracic and Ca.08). These results prompted a new generation of larger ran-
domized controlled trials to attempt to validate the observa-
tions made in the meta-analysis. The outcome information
from the studies enrolling more than 300 patients and com-
paring surgery alone with surgery followed by chemother-
apy is presented in Table 1. This review does not address
the use of postoperative tegafur and uracil. Although Japa-
nese trials have demonstrated a survival benefit with adju-
vant tegafur and uracil, no confirmatory trials have been
performed in Western populations, and this agent is not
presently available in the United States.3Adjuvant Therapy Trials Showing Differences in
Survival
Three of the six trials listed in Table 1 reported a statisti-
cally significant survival advantage for the patients treated
with chemotherapy after resection. In the initial study, re-
ferred to as the International Adjuvant Lung Trial (IALT),
1867 patients with stage I to IIIA NSCLC who underwent
a complete resection of their tumor were randomly assigned
to either observation or cisplatin given for 3 to 4 cycles
combined with etoposide (56%), vinblastine (11%), vinor-
elbine (27%), or vindesine (6%).4 Radiotherapy was ad-
ministered to 474 patients (25%). Although the study was
terminated early because of slow accrual (3300 patients ini-
tially planned), there was a significant improvement in sur-
vival in favor of the chemotherapy arm (HR, 0.86; 95% CI,
0.76 to 0.98; P<.03), translating into an absolute gain of
4.1% at 5 years (from 40.4% to 44.5%). No significant in-
teraction with pathologic stage was observed. An updated
report after 7 years of follow-up, however, revealed that
the overall survival advantage was no longer significant
(HR, 0.91; 95% CI, 0.81 to 1.02; P ¼ .10).5 This late loss
of survival benefit appeared to be due to an excess of
noncancer-related deaths in the chemotherapy arm.rdiovascular Surgery c Volume 144, Number 3 S39
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ALPI ¼ Adjuvant Lung Project Italy
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Trialist Association
BLT ¼ Big Lung Trial
CALGB ¼ Cancer and Leukemia Group B
CI ¼ confidence interval
HR ¼ hazard ratio
IALT ¼ International Adjuvant Lung Trial
LACE ¼ Lung Adjuvant Cisplatin Evaluation
NSCLC ¼ non–small cell lung cancer0 The JoThe National Cancer Institute of Canada Clinical Trials
Group reported another adjuvant chemotherapy trial
(JBR.10), which showed a difference in patient outcome.6
In that trial, 482 patients with completely resected stage
IB or II NSCLC were randomized to postoperative observa-
tion or vinorelbine and cisplatin for 4 cycles. No chest ra-
diotherapy was administered. After a median follow-up of
5.1 years, overall survival was significantly prolonged for
the patients treated with surgery plus chemotherapy com-
pared with those treated with surgical resection alone (HR
for death, 0.69; 95% CI, 0.52 to 0.91; P ¼ .04). The corre-
sponding 5-year survival rates were 69% and 54%. An up-
dated survival analysis of the JBR.10 trial reported
a persistent survival advantage for patients treated with ad-
juvant chemotherapy after more than 9 years of follow-up.7
In both these reports, the benefit was restricted to patients
with resected stage II disease and was not seen in the sub-
jects with stage I NSCLC.
The Adjuvant Navelbine International Trialist Associa-
tion (ANITA) study also examined vinorelbine and cisplatin
after resection of the participants’ lung cancer.8 A total of
840 patients with stage IB-IIIA NSCLCwho had undergone
successful surgical resection were randomly assigned to ei-
ther observation or chemotherapy for 4 cycles. Postopera-
tive radiotherapy was delivered to 282 patients (28%).
Adjuvant chemotherapy was associated with significantly
improved survival (HR, 0.80; 95% CI, 0.66 to 0.96; P ¼
.017). This benefit was observed in patients with stage II
and IIIA NSCLC. The 5-year survival rate for those with
stage I, II, and IIIAwas 62%, 52%, and 42% in the chemo-
therapy arm compared with 63%, 39%, and 26% in the ob-
servation arm, respectively.
Negative Adjuvant Therapy Trials
The benefits of postoperative chemotherapy were chal-
lenged by 3 other randomized trials completed after the
1995 meta-analysis, all of which failed to show a signifi-
cant survival advantage for adjuvant chemotherapy. The
Adjuvant Lung Project Italy (ALPI) studied patients withurnal of Thoracic and Cardiovascular Surgresected stage I-IIIA NSCLC by randomly allocating
them to treatment with mitomycin, vindesine, and cisplatin
every 3 weeks for 3 cycles or observation after complete
surgical resection.9 Postoperative thoracic radiotherapy
was allowed at the discretion of each participating site.
A total of 1088 patients were analyzed after a median
follow-up period of 64.5 months. In the chemotherapy
arm, 69% of patients completed the mitomycin, vindesine,
and cisplatin treatment and one half required dose modifi-
cations or omission of part of the planned regimen. No dif-
ference was found between the outcomes of patients
treated with resection plus chemotherapy versus those
treated with surgery alone (HR for death, 0.96; 95% CI
0.81 to 1.13; P ¼ .589). The use of the chemotherapy reg-
imen of mitomycin, vindesine, and cisplatin is considered
inferior by today’s standards and might have led to the
high death rates during the first year after randomization
and the poor compliance with chemotherapy, 2 strong crit-
icisms of the study. Similarly, no benefit from adjuvant
cisplatin-based chemotherapy was seen among 381 pa-
tients with stage I-III NSCLC in the Big Lung Trial
(BLT).10 However, the trial was underpowered to detect
the magnitude of difference in survival observed in the
other trials, and a considerable proportion (15%) of pa-
tients had undergone microscopically incomplete surgical
resection.
The Cancer and Leukemia Group B (CALGB) 9633 trial
was unique in limiting enrollment to patients with resected
stage IB NSCLC who were randomized to treatment with
paclitaxel and carboplatin every 3 weeks for 4 cycles or to
observation.11 The study was terminated early when an in-
terim analysis in 2004 suggested a significantly greater sur-
vival rate with adjuvant therapy. After a reanalysis of the
data in 2006, the survival benefit still favored chemotherapy
but was no longer significant (HR, 0.83; 90% CI, 0.64 to
1.08; P ¼ 0.12). With 344 patients, CALGB 9633 might
have lacked statistical power to detect small, but meaning-
ful, improvements in survival in this relatively good risk
population. Furthermore, the use of a carboplatin regimen
instead of a cisplatin backbone might have affected the re-
sults, because a recent meta-analysis demonstrated
cisplatin-based chemotherapy to be slightly superior to car-
boplatin regimens for advanced NSCLC.12
Meta-Analyses
A meta-analysis (Lung Adjuvant Cisplatin Evaluation
[LACE]) combining individual patient data from 4584 pa-
tients from the 5 large adjuvant cisplatin-chemotherapy tri-
als described earlier in the present review (ALPI, BLT,
IALT, ANITA, and JBR.10) has been published.13 The anal-
ysis confirmed a statistically significant benefit in overall
survival for chemotherapy compared with observation
(HR, 0.89; 95% CI, 0.82 to 0.96; P ¼ .005), corresponding
to an absolute gain of 5.4% at 5 years. The benefits ofery c September 2012
TABLE 1. Overview of adjuvant chemotherapy trials enrolling more than 300 patients published after 1995 non–small cell lung cancer
meta-analysis
Trial Patients (n) Stage eligibility
Absolute difference in
5-year survival (%) HR for death 95% CI P value
IALT4 1867 I-III 4.1 0.86 0.76–0.98 <.03
JBR.106 482 IB-II 15 0.69 0.52–0.91 .04
ANITA8 840 IB-IIIA 8.6 0.80 0.66–0.96 .017
ALPI9 1088 I-IIIA 1 0.96 0.81–1.13 .589
BLT10 381 I-III NA 1.02 0.77–1.35 .9
CALGB 963311 344 IB 2 0.83 0.64–1.08 .125
HR, Hazard ratio; CI, confidence interval; IALT, International Adjuvant Lung Trial; ANITA, Adjuvant Navelbine International Trialist Association; ALPI, Adjuvant Lung Project
Italy; BLT, Big Lung Trial; NA, not available; CALGB, Cancer and Leukemia Group B.
Heon and Johnson Session III: Lung Cancer—Other Considerationschemotherapy were confined to patients with resected stage
II or III NSCLC. A suggestion of a worse outcome with
adjuvant chemotherapy for the 347 patients with stage IA
disease was found (HR, 1.40; 95% CI, 0.95 to 2.06). The
LACE meta-analysis also found a trend for longer survival
for the patients treated with cisplatin plus vinorelbine versus
cisplatin plus 1 or 2 other drugs. However, the greater
planned doses of cisplatin in the cisplatin- and
vinorelbine-treated patients might have been responsible
for the observations. Finally, an update of the 1995
meta-analysis presented at the 2007 Annual Meeting of
the American Society of Clinical Oncology showed a con-
sistent benefit with adjuvant chemotherapy for surgically
resected NSCLC, with an overall benefit of 4% at 5 years.14
Thus, 3 randomized trials of postoperative cisplatin-based
chemotherapy (IALT, JBR.10, and ANITA) and 2 large indi-
vidual patient data meta-analyses have convincingly dem-
onstrated that cisplatin-doublet adjuvant chemotherapy
causes a statistically significant and clinically meaningful
survival advantage for patients with resected early-stage
NSCLC. The most consistent benefit has been reported for
patients with surgically resected stage II and IIIA NSCLC.
From this evidence, postoperative adjuvant cisplatin-based
chemotherapy is now the standard of care for the manage-
ment of completely resected stage II and IIIA NSCLC.15Potential Candidates for Adjuvant Chemotherapy
Stage IB NSCLC with adverse prognostic factors. Evi-
dence is not yet available from the randomized trials or
the LACE meta-analysis to routinely recommend adjuvant
chemotherapy for resected stage IB disease. The CALGB
9633 trial was composed exclusively of patients with stage
IB NSCLC. The study design showed that patients given
paclitaxel and carboplatin lived slightly longer but the dif-
ference did not reach significance for the overall population.
However, in an unplanned subset analysis, the trial reported
significant disease-free and overall survival benefits in favor
of postoperative chemotherapy for patients with tumors 4
cm or greater in diameter (HR for death, 0.69; P ¼ .043).
In a similar exploratory subgroup analysis of the JBR.10
trial, patients with stage IB disease with tumors 4 cm orThe Journal of Thoracic and Cagreater showed a trend toward improved survival rates
with adjuvant chemotherapy.7 However, there are currently
no prospectively validated data supporting a survival benefit
with adjuvant chemotherapy in patients with stage IB
NSCLC and larger tumors. Likewise, the presence of vis-
ceral pleural invasion identifies a group of stage IB patients
with poorer prognosis. In a large retrospective analysis of
9758 patients who underwent surgical resection of NSCLC,
the Japanese Joint Committee for Cancer Registration dem-
onstrated poorer survival of resected T2 tumors with vis-
ceral pleural invasion (5-year overall survival rate,
53.0%) compared with T2 tumors without visceral pleural
invasion (61.6%; P<.001).16 However, no analyses have
yet reported on the effect of adjuvant chemotherapy in
node-negative T2 tumors according to visceral pleural in-
volvement. Given the currently available information, we
strongly recommend considering patients with stage IB dis-
ease and larger tumors (4 cm) for cisplatin-based adjuvant
chemotherapy on an individualized basis. Similarly, postop-
erative chemotherapy might be an option for select patients
with resected node-negative T2 tumors with visceral pleural
invasion given their poorer prognosis for survival.
T3 with separate tumor nodules in the same lobe. Data
are not specifically available to inform the use of adjuvant
chemotherapy for patients with separate tumor nodules in
the same lobe as the primary tumor, without lymph node in-
volvement. Tumors with same-lobe nodules were reclassi-
fied as stage T3 instead of T4 on the basis of the similar
survival rates in the 7th edition of the TNM staging system
for lung cancer of the American Joint Committee on Can-
cer.1 Our de facto practice is to consider these patients
with T3 tumors with separate tumor nodules in the same
lobe for cisplatin-based adjuvant chemotherapy because
of their similar survival to patients with T3 tumors without
satellite nodules and data supporting adjuvant systemic
therapy for resected stage II NSCLC.
Resected oligometastatic NSCLC. Retrospective studies
have suggested that highly selected patients with NSCLC
and a solitary synchronous site of extrathoracic metastatic
disease, usually brain or adrenal, can be effectively treatedrdiovascular Surgery c Volume 144, Number 3 S41
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have investigated the value of chemotherapy after surgical
removal of the primary tumor and isolated metastasis.
On the basis of the established benefit of adjuvant
chemotherapy, it would seem reasonable to include
chemotherapy in the treatment of patients who have
undergone resection of an isolated metastasis and primary
tumor with curative intent.FUTURE STRATEGIES
Current research efforts aim at identifying subsets of pa-
tients who will derive the greatest benefit from adjuvant
chemotherapy by using pharmacogenomic approaches
and gene-expression profiling. Moreover, modern adjuvant
therapy trials are attempting to integrate novel biological
therapeutic agents, such as bevacizumab, into standard
treatment paradigms. The addition of bevacizumab to pac-
litaxel and carboplatin has been successful in advanced
NSCLC and is now being investigated in the early-stage set-
ting within the context of a large Intergroup phase III ran-
domized controlled trial (E1505/NCT00324805). In that
trial, patients with resected stage IB (4 cm), II, and IIIA
NSCLC are randomized to receive adjuvant cisplatin-
based doublet chemotherapy, with or without bevacizumab.
The optimal adjuvant therapy for patients whose tumors
harbor activating mutations of the epidermal growth factor
receptor is also being studied. Subjects with resected
NSCLC and epidermal growth factor receptor mutations
are being treated with adjuvant chemotherapy with or with-
out a tyrosine kinase inhibitor of the epidermal growth fac-
tor receptor (NCT00567359). Whether these approaches
will improve on the current standard of adjuvant cisplatin-
based doublet chemotherapy remains to be determined.CONCLUSIONS
The treatment of early-stage NSCLC has undergone
a paradigm shift during the past 7 to 8 years with the addi-
tion of systemic therapy to local therapy. Several large
randomized controlled trials and 2meta-analyses have dem-
onstrated a survival advantage for patients with stage II and
IIIA NSCLC treated with adjuvant chemotherapy compared
with those who underwent observation. Adjuvant platinum-
based chemotherapy is now considered the standard of care
for patients with stage II and IIIA NSCLC and can be con-
sidered an option for select patients with stage IB disease
and adverse prognostic factors (primary tumor 4 cm, T2
tumor with visceral pleural invasion), patients with T3 tu-
mors with same-lobe nodules, and those with resected oli-
gometastatic disease. In this era of personalized targeted
therapy, research is ongoing to individualize systemic ther-
apy for early-stage NSCLC and to integrate novel biological
therapeutic agents into the treatment paradigm.S42 The Journal of Thoracic and Cardiovascular SurgReferences
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